ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors

Inclusion Criteria:

1. Participants with advanced solid tumor that is not amenable to surgical resection or
other approved therapeutic options.

2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2.

3. Participants must have measurable disease per Response Evaluation Criteria In Solid
Tumors (RECIST) version 1.1 or disease evaluable by assessment of tumor antigens:

- Participants with non-evaluable or non-measurable cancer are eligible if they have a
confirmed increase in tumor antigens >=2 x upper limit of normal (ULN).

4. All participants must consent to provide archived diagnostic formalin-fixed paraffin
embedded (FFPE) tumor tissue and on study biopsies.

5. Participant has adequate bone marrow, renal, hepatic and cardiac function.

6. Women of childbearing potential must have a negative serum pregnancy test within 14
days prior to initiation of treatment.

Exclusion Criteria:

1. Participant has received anticancer therapy or any investigational therapy within a
period of 21 days prior to the first dose of ABBV-085.

2. Uncontrolled metastases to the central nervous system (CNS). Participants with brain
metastases are eligible provided they have shown clinical and radiographic stable
disease for at least 4 weeks after definitive therapy and have not used steroids for
at least 4 weeks prior to first dose of ABBV-085.

3. Unresolved adverse events >= Grade 2 from prior anticancer therapy, except for
alopecia.

4. Participant has ongoing hemolysis.

5. Major surgery within <=28 days prior to the first dose of ABBV-085.

6. Clinically significant uncontrolled condition(s).

7. Participant has history of major immunologic reaction to any auristatin-based and /or
Immunoglobulin G (IgG) containing agent.